Media headlines about AngioDynamics (NASDAQ:ANGO) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AngioDynamics earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 45.9264225667901 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of analysts recently weighed in on the company. KeyCorp restated a “hold” rating on shares of AngioDynamics in a report on Friday, August 25th. BidaskClub upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Barclays PLC decreased their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Wednesday, July 19th. Finally, Canaccord Genuity restated a “hold” rating and issued a $17.00 price objective on shares of AngioDynamics in a report on Tuesday, July 18th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $18.50.

Shares of AngioDynamics (NASDAQ:ANGO) traded up 0.42% during mid-day trading on Thursday, reaching $16.76. The company’s stock had a trading volume of 36,370 shares. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $18.18. The company’s 50-day moving average is $16.36 and its 200 day moving average is $16.20. The firm has a market cap of $613.08 million, a price-to-earnings ratio of 122.34 and a beta of 1.15.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The company had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. During the same quarter last year, the business posted $0.19 EPS. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. On average, equities analysts anticipate that AngioDynamics will post $0.67 EPS for the current year.

In related news, CEO James C. Clemmer acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The stock was bought at an average price of $15.79 per share, for a total transaction of $78,950.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Clemmer acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were bought at an average price of $15.64 per share, with a total value of $312,800.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at $1,355,722.12. The disclosure for this purchase can be found here. Insiders have purchased a total of 25,316 shares of company stock valued at $396,806 in the last quarter. 1.88% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “AngioDynamics (ANGO) Given Media Impact Rating of 0.24” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/31/angiodynamics-ango-given-media-impact-rating-of-0-24.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Insider Buying and Selling by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.